---
title: "Myriad Genetics Q2 FY26 operating loss narrows to $38.9 million; revenue drops 11% to $190.7 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294412137.md"
description: "Myriad Genetics reported Q2 FY26 revenue of $190.7 million, an 11% decline, with a narrowed operating loss of $38.9 million. Gross margin fell to 66.6%, and test volumes dropped 1%. The company revised its full-year revenue outlook to $790 million, suspended adjusted EBITDA guidance, and launched the Ascend efficiency initiative."
datetime: "2026-07-30T20:32:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294412137.md)
  - [en](https://longbridge.com/en/news/294412137.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294412137.md)
generator: "portal-rs"
---

# Myriad Genetics Q2 FY26 operating loss narrows to $38.9 million; revenue drops 11% to $190.7 million

-   Myriad Genetics Q2 2026 revenue fell 11% to $190.7 million; net loss narrowed to $43.2 million, or $0.46 per share. \* Gross margin dropped 4.6 percentage points to 66.6%; operating loss narrowed to $38.9 million. \* Test volumes slipped 1% to 379,000; average revenue per test fell 9%, partly reflecting an $11 million revenue reduction tied to cash-collection estimates. \* Cancer Care Continuum volumes rose 6% to 95,000 while revenue fell 11% to $114.1 million; Prenatal Health volumes fell 9% to 144,000. \* Revised FY 2026 revenue outlook to $770-$790 million; suspended adjusted EBITDA guidance while launching the Ascend efficiency initiative. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000899923-26-000070), on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MYGN.US](https://longbridge.com/en/quote/MYGN.US.md)

## Related News & Research

- [Myriad Q2 revenue misses estimates, cuts 2026 revenue outlook](https://longbridge.com/en/news/294411320.md)
- [Myriad Genetics: Q2 Miss, Guidance Cut Lead to Lower $4 Price Target and Maintained Hold Rating](https://longbridge.com/en/news/294446991.md)
- [Better Buy: Palantir at 108 Times Forward Earnings or Tesla at 190 Times?](https://longbridge.com/en/news/296261059.md)
- [Myriad Uranium wins final court approval for Rush Rare Metals acquisition](https://longbridge.com/en/news/296538572.md)
- [International Bancshares Q2 net income falls on higher credit loss provision](https://longbridge.com/en/news/295130370.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**